STOCK TITAN

Can-Fite Biopharma Ltd - CANF STOCK NEWS

Welcome to our dedicated news page for Can-Fite Biopharma (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite Biopharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Can-Fite Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Can-Fite Biopharma's position in the market.

Rhea-AI Summary
Can-Fite BioPharma's novel approach for the treatment of advanced liver cancer will be presented at the ASCO Breakthrough Meeting in Japan on August 4th, 2023. Namodenoson, currently in a Phase 3 study for the treatment of advanced hepatocellular carcinoma (HCC), has cleared cancer in a patient from a prior Phase 2b study who remains cancer-free for over 6 years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.3%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.62%
Tags
conferences acquisition
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.36%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.1%
Tags
conferences
-
Rhea-AI Summary
Can-Fite BioPharma announces financial results and clinical developments for Q1 2023. Highlights include progress in liver cancer and pancreatic cancer studies, positive opinion from EMA for psoriasis study, and new management structure. Revenues decreased slightly, research and development expenses increased, and net loss increased compared to Q1 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.88%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.27%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.43%
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
none
Can-Fite Biopharma Ltd

NYSE:CANF

CANF Rankings

CANF Stock Data

13.61M
1.22B
4.89%
0.18%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Israel
P O Box 7537

About CANF

can fite biopharma (canfy) is a biotechnology company based out of 10 bareket street, פ"ת, israel.